Market revenue in 2023 | USD 157.0 million |
Market revenue in 2030 | USD 249.4 million |
Growth rate | 6.8% (CAGR from 2023 to 2030) |
Largest segment | Hereditary non-cancer testing |
Fastest growing segment | Hereditary Cancer Testing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hereditary Cancer Testing, Hereditary Non-cancer Testing |
Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Illumina Inc, Natera Inc, Labcorp Holdings Inc, Roche Holding AG ADR, Quest Diagnostics Inc, CooperSurgical, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Twist Bioscience Corp, Sophia Genetics SA, Fulgent Genetics Inc, MedGenome, Centogene NV Ordinary Shares, The Cooper Companies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary testing market will help companies and investors design strategic landscapes.
Hereditary non-cancer testing was the largest segment with a revenue share of 68.6% in 2023. Horizon Databook has segmented the Netherlands hereditary testing market based on hereditary cancer testing, hereditary non-cancer testing covering the revenue growth of each sub-segment from 2018 to 2030.
Efforts undertaken by researchers and healthcare providers to improve awareness about DNA testing for inherited genetic conditions can be attributed to the market’s revenue generation the Netherlands. For instance, in May 2018, doctors from teaching hospitals in Groningen and Friesland provinces of the Netherlands provided DNA tests for detection of inherited genetic illness risk in babies.
The doctors offered these tests for USD 1,064.71 (€ 950) that are not covered by health insurance. This product development expanded DNA testing of inherited genetic disorders in the Netherlands. The implementation of newborn screening in the Netherlands for detection of SCID is a multifaceted process that involves several government agencies.
In 2015, Dutch Ministry of Health and Dutch Health Council included SCID screening in a Dutch newborn screening program that was started in 1974. The number of newborn screenings has increased significantly.
Horizon Databook provides a detailed overview of country-level data and insights on the Netherlands hereditary testing market, including forecasts for subscribers. This country databook contains high-level insights into Netherlands hereditary testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account